The 2021 Sexually Transmitted Infections (STIs) Treatment Guidelines, published by the Centers for Disease Control and Prevention (CDC), provide updated recommendations for the treatment of STIs. The guidelines cover a range of infections, including Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, and Mycoplasma genitalium. They also address new treatments such as the addition of metronidazole to pelvic inflammatory disease (PID) regimens and alternative treatments for bacterial vaginosis. The guidelines emphasize the importance of prevention strategies, diagnostic recommendations, and counseling messages. Key areas include human papillomavirus (HPV) vaccine recommendations, expanded risk factors for syphilis testing in pregnant women, one-time testing for hepatitis C, evaluation of men who have sex with men after sexual assault, and two-step testing for genital herpes simplex virus. The guidelines are intended to assist healthcare providers in preventing and treating STIs, with a focus on clinical management and counseling. They are applicable in various healthcare settings and complement quality clinical services guidelines for STIs and HIV. The development process involved systematic literature reviews, expert consultations, and public input, ensuring evidence-based recommendations. The guidelines also provide clinical prevention guidance, emphasizing risk assessment, pre-exposure vaccination, identification of asymptomatic infections, effective diagnosis and treatment, and evaluation of sex partners. Specific methods for primary prevention, such as pre-exposure vaccination, condom use, and male circumcision, are discussed, along with emergency contraception and partner services. The guidelines aim to reduce STI transmission and improve public health outcomes.The 2021 Sexually Transmitted Infections (STIs) Treatment Guidelines, published by the Centers for Disease Control and Prevention (CDC), provide updated recommendations for the treatment of STIs. The guidelines cover a range of infections, including Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, and Mycoplasma genitalium. They also address new treatments such as the addition of metronidazole to pelvic inflammatory disease (PID) regimens and alternative treatments for bacterial vaginosis. The guidelines emphasize the importance of prevention strategies, diagnostic recommendations, and counseling messages. Key areas include human papillomavirus (HPV) vaccine recommendations, expanded risk factors for syphilis testing in pregnant women, one-time testing for hepatitis C, evaluation of men who have sex with men after sexual assault, and two-step testing for genital herpes simplex virus. The guidelines are intended to assist healthcare providers in preventing and treating STIs, with a focus on clinical management and counseling. They are applicable in various healthcare settings and complement quality clinical services guidelines for STIs and HIV. The development process involved systematic literature reviews, expert consultations, and public input, ensuring evidence-based recommendations. The guidelines also provide clinical prevention guidance, emphasizing risk assessment, pre-exposure vaccination, identification of asymptomatic infections, effective diagnosis and treatment, and evaluation of sex partners. Specific methods for primary prevention, such as pre-exposure vaccination, condom use, and male circumcision, are discussed, along with emergency contraception and partner services. The guidelines aim to reduce STI transmission and improve public health outcomes.